login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
OMEROS CORP (OMER) Stock News
NASDAQ:OMER -
US6821431029
-
Common Stock
4.16
USD
-0.07 (-1.65%)
Last: 8/29/2025, 8:00:02 PM
4.15
USD
-0.01 (-0.24%)
After Hours:
8/29/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OMER Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Chartmill
Omeros Corp (NASDAQ:OMER) Reports Q2 2025: Narrowed Losses, Regulatory Progress, and Market Optimism
17 days ago - By: The Motley Fool
Omeros Posts 2,652 Percent Sales Jump
17 days ago - By: Omeros Corporation
Omeros Corporation Reports Second Quarter 2025 Financial Results
17 days ago - By: Benzinga
- Mentions:
BTCM
DE
TIC
DFLI
...
Earnings Scheduled For August 14, 2025
20 days ago - By: Omeros Corporation
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
a month ago - By: ACCESS Newswire
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
a month ago - By: Omeros Corporation
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
2 months ago - By: Omeros Corporation
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
2 months ago - By: Omeros Corporation
Omeros Announces Webcast Details for Annual Meeting of Shareholders
4 months ago - By: Omeros Corporation
Omeros Corporation Reports First Quarter 2025 Financial Results
4 months ago - By: Benzinga
Examining the Future: Omeros's Earnings Outlook
4 months ago - By: Omeros Corporation
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
4 months ago - By: Omeros Corporation
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
4 months ago - By: Omeros Corporation
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
5 months ago - By: Omeros Corporation
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
5 months ago - By: Omeros Corporation
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
5 months ago - By: Omeros Corporation
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
Please enable JavaScript to continue using this application.